On November 20, 2019 Thyas reported that it has raised JPY 240 million in Series A2 financing on November 20, with participation from Kyoto University Innovation Capital Co., Ltd., Chushin Venture Capital Co., Ltd., and Future Venture Capital Co., Ltd. (Press release, Thyas , NOV 20, 2019, View Source [SID1234629210]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funds will be used for accelerating the research and development including preclinical studies of iPS cell-derived T cell therapy for the treatment of solid cancers.